Day: June 1, 2022

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, today announced the appointment of Patrick Gallagher, MBA, MPH, as chief business officer. “Patrick is an accomplished biotech executive who brings significant strategic and transactional expertise to Sensei. He has worked across the biotechnology, Big Pharma, venture and banking sectors and has a track record of tailoring partnerships and transactions to build value,” said John Celebi, president and chief executive officer of Sensei Biotherapeutics. “We’re thrilled to add him to our leadership team at a pivotal moment as we work to optimize both of our platforms and advance key programs towards important milestones.” Mr. Gallagher has...

HOUSTON and MIDLAND, Texas, June 01, 2022 (GLOBE NEWSWIRE) — Kinetik Holdings Inc. (NASDAQ: KNTK) (“Kinetik”) announced today that its subsidiary, Kinetik Holdings LP (the “Issuer”), intends to offer $1.0 billion aggregate principal amount of sustainability-linked senior notes due 2030 (the “Senior Notes”) in an offering (the “Offering”) pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The Senior Notes will be fully and unconditionally guaranteed by Kinetik. The Issuer intends to use the net proceeds from the Offering, together with borrowings under a new 3-year unsecured term loan facility with a group of commercial banks, to refinance all of its existing consolidated indebtedness. The interest rate on the Senior Notes will be linked to Kinetik’s performance against sustainability...

SARASOTA, Fla., June 01, 2022 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (NYSE: ROP) today announced that it has agreed to sell a majority stake in its industrial businesses, including its entire Process Technologies segment and the industrial businesses within its Measurement & Analytical Solutions segment, to affiliates of Clayton, Dubilier & Rice, LLC (“CD&R”). Roper will receive total upfront, pre-tax cash proceeds of approximately $2.6 billion while retaining a 49% minority interest in a new standalone entity. The transaction includes the following businesses: Alpha, AMOT, CCC, Cornell, Dynisco, FTI, Hansen, Hardy, Logitech, Metrix, PAC, Roper Pump, Struers, Technolog, Uson, and Viatran. Collectively, these businesses generated approximately $940 million of revenue and $260 million of EBITDA in 2021. “This...

HIGH POINT, N.C., June 01, 2022 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd (“G42 Investments”). Under the terms of the agreements, G42 Investments acquired 10,386,274 shares of Class A Common Stock of vTv at an issue price of $2.407 per share, with $12.5 million paid in cash at closing, and the remaining amount of $12.5 million payable on May 31, 2023. The agreements also provide for the potential issuance of $30 million in additional shares of Class A Common Stock to G42 Investments (or cash in lieu of such issuance at the option of G42 Investments) if the United States Food and Drug Administration (the “FDA”) approves the marketing and sale of a pharmaceutical product containing TTP399, a liver selective...

Accomplished executive brings deep expertise leading global strategy and corporate development CHICAGO, June 01, 2022 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) has hired Karen Krause as Executive Vice President, Chief Strategy and Communications Officer, effective June 1. Karen brings deep strategy and corporate development expertise in financial services with extensive experience in growing businesses through acquisitions and transforming operations to grow capabilities globally. She will be responsible for leading TransUnion’s Global Strategy, Communications and Branding functions, with a focus on enabling, facilitating and monitoring our transformation across global platforms and products to achieve our vision and strategy. She will partner with Finance and the Business to support our growth in relation to future M&A priorities. “TransUnion...

— Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter — — Expected approval mid-year 2023, if accepted by FDA for filing, based on feedback from U.S. Food and Drug Administration (“FDA”) provided during AOP Health’s Type C meeting — — Enrollment of study of pediatric patients with supraventricular tachycardia is underway in Europe and is designed to serve as the basis for proposed pediatric study plans for a future FDA submission — — If landiolol is approved, Eagle expects five years of new chemical entity exclusivity — WOODCLIFF LAKE, N.J., June 01, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced...